Paydas S, Balal M, Demir E, Sertdemir Y, Erken U
Department of Nephrology, Cukurova University Faculty of Medicine, Adana, Turkey.
Transplant Proc. 2011 Apr;43(3):863-6. doi: 10.1016/j.transproceed.2011.02.072.
Avascular osteonecrosis (AVN) is a complication of renal transplantation. In this study, we present 12 cases of AVN associated with renal transplantation.
Renal transplant recipients (RTRs) with AVN (group I [GI]) were evaluated by using magnetic resonance imaging and blood urea nitrogen, creatinine, glucose, calcium, phosphorus, magnesium, alkaline phosphatase, parathyroid hormone, and urine analysis. We evaluated bone mineral density (BMD) of the femoral neck and lumbar vertebrae. All patients were treated with steroids, cyclosporine, or tacrolimus plus mycophenolate mofetil. Twenty-six RTRs (GII) without AVN were randomly selected as control subjects.
The mean ages of GI and GII, were 33.81 ± 6.72 and 34.00 ± 7.65 years respectively (P > .05). The mean interval between transplantation and development of AVN was 12.08 ± 6.48 months. Although levels of blood urea nitrogen, creatinine, calcium, magnesium, and parathyroidhormone, as well as glucocorticoid doses in the first 12 months were similar in GI and GII, there were significant differences in serum alkaline phosphatase, hemoglobin levels, and white blood cell count between GI and GII (P < .05 for each). BMD T score <-1.5 was observed in 8/9 GI and 15/26 patients in GII. All of the patients with AVN except 1, were followed with conservative measures including calcium, magnesium, and vitamin D replacement therapies, bisphosphonate, and reduced or ceased glucocorticoid treatment. Although T scores of the femoral head were similar in GI and GII, the lumbar vertebral T score was significantly lower in GI than in GII (P < .052).
AVN developed within the first year after transplantation. Decreased lumbar vertebral BMD, which can be an indicator of glucocorticoid effect, accompanied AVN in nearly all patients. Despite the absence of renal dysfunction, increased bone destruction, anemia, and leucocytosis were coincidental or accompanying findings in our patients with AVN.
缺血性骨坏死(AVN)是肾移植的一种并发症。在本研究中,我们报告了12例与肾移植相关的AVN病例。
对患有AVN的肾移植受者(RTRs,第一组[GI])采用磁共振成像以及血尿素氮、肌酐、葡萄糖、钙、磷、镁、碱性磷酸酶、甲状旁腺激素和尿液分析进行评估。我们评估了股骨颈和腰椎的骨密度(BMD)。所有患者均接受类固醇、环孢素或他克莫司加霉酚酸酯治疗。随机选择26例无AVN的RTRs(GII)作为对照。
GI组和GII组的平均年龄分别为33.81±6.72岁和34.00±7.65岁(P>.05)。移植至发生AVN的平均间隔时间为12.08±6.48个月。尽管GI组和GII组的血尿素氮、肌酐、钙、镁和甲状旁腺激素水平以及前12个月的糖皮质激素剂量相似,但GI组和GII组的血清碱性磷酸酶、血红蛋白水平和白细胞计数存在显著差异(每组P<.05)。GI组9例中有8例、GII组26例中有15例的BMD T评分<-1.5。除1例患者外,所有AVN患者均采用包括补充钙、镁和维生素D、双膦酸盐以及减少或停用糖皮质激素治疗在内的保守措施进行随访。尽管GI组和GII组股骨头的T评分相似,但GI组腰椎的T评分显著低于GII组(P<.052)。
AVN在移植后第一年内发生。腰椎BMD降低,这可能是糖皮质激素作用的一个指标,几乎在所有患者中都与AVN同时出现。尽管没有肾功能障碍,但骨破坏增加、贫血和白细胞增多是我们AVN患者的偶发或伴随表现。